Product Images Everolimus

This text provides information about an oral medication named Everolimus Tablets with a strength of 10mg, containing 28 tablets in a carton. The package insert provides details on the dosage. The medication should be stored in the original container, protected from light and moisture, at a temperature between 15-30°C. The drug is manufactured by Natco Pharma Limited in India. The NDC number, strength, count, and artwork dimensions are also given.*

This is a set of labels for Everolimus Tablet in 10mg dosage, manufactured by Natco Pharma Ltd. They are only available with the prescription and should be stored at temperatures ranging from 15-30°C (59-88°F). The original container should be used for storage, and it should be protected from light and moisture. The batch number and expiration date are mentioned on the label. The given text seems to repeat the same information on multiple labels, along with some additional production details such as width and thickness.*

This appears to be a description of a medication called Everolimus Tablet, available in 2.5 mg and 5 mg doses. The tablets are meant to be stored at room temperature and the packaging includes specific information about printing colors, foil width, and dimensions. However, some of the text is unclear due to errors.*

Product Name: Everolimus Tablets, Strength: 2.5 mg, Count: 28's. The tablets are meant for oral use and the dosage can be found in the package insert. They should be stored at 25°C (77°F) with permitted excursions between 15-30°C (59-86°F), in the original container and protected from light and moisture. The manufacturer is Natco Pharma Limited, located in India. The tablets are available only on prescription (Rx Only) and are packaged in blisters of 7, with 4 such blisters included in one carton. No additional useful information could be retrieved.*

This is a medication called Everolimus Tablets. Each tablet contains 5 mg of everolimus. The package contains 28 tablets and should be stored in the original container at a temperature between 15-30°C (59-86°F). The medication is for oral use and its dosage should be checked on the package insert. It is important to protect the container from light and moisture and to keep it away from children. The medication is manufactured by Natco Pharma Limited in India and the product is only available with a prescription. There are also details about the packaging size, dimensions, font type and size, as well as colors used for printing.*

This is a description of Everolimus Tablets, each containing 5 mg medicine, manufactured by Natco Pharma Limited. The tablets are meant for prescription-only consumption and need to be stored in the original container, protected from light and moisture at temperatures ranging from 15-30°C (58-86°F). The lot number and expiration date vary across different batches.*

This text contains information about a medication called Everolimus Tablet with a strength of 7.5 mg. It provides instructions for storage, including the temperature range and protection from light and moisture. The manufacturer of the medication is Natco Pharma Ltd. There are also references to the National Drug Code (NDC) for the medication. The text does not provide any additional information.*

This appears to be a medical document that lists symptoms related to various body systems including gastrointestinal, nervous, respiratory, and skin. It also mentions investigations, metabolism, and nutrition. However, some of the text is not readable due to errors.*

This is a report on the analysis of Everclimus tablets with and without Exemestane in terms of median progression-free survival and objective response rate. The data is based on a sample size of 485 patients with Exemestane and 238 without. The report includes hazard ratios, p-values, and details on the methodology used in the analysis.*

This appears to be a table summarizing the results of a clinical trial evaluating the efficacy of Everolimus tablets versus placebo in terms of progression-free survival. The table presents the number of patients included in the trial, the median progression-free survival time in months, and hazard ratios and p-values for the treatment versus the control group. Additionally, the table appears to include information on adjudication for discrepancies in assessments between the investigator review and the central review.*

The text seems to be a report or analysis of a drug called Everolimus tablets and its effectiveness in treating a disease. The report includes data on disease progression, survival, and overall response rate. It also mentions a hazard ratio that was obtained from a model. However, the specific details and context of the analysis are not clear, and some of the characters are not readable.*

This appears to be a list of symptoms and related information organized by body system. The symptoms include gastrointestinal issues (nausea, vomiting, constipation), tiredness, fever, headaches, and rashes. Some of the symptoms are scored according to the NGI CTCAE Version 30. It is unclear what the context is or what condition this information relates to.*

The given text contains a table showing laboratory parameters for two drug treatments: Everolimus Tablets with Exemestane and Placebo with Exemestane. The table includes various values for Hematology and Chemistry parameters such as leukopenia, thrombocytopania, hypercholesterolemia, increased AST, and increased ALT, among others. The parameters are graded according to NCI CTCAE Version 10, but no details are given on what these grades indicate. The text mentions that certain adverse drug reactions were reported, although they were infrequent. Also, some Grade 4 laboratory abnormalities were reported.*

Not available.*